Pulmonary Alveolar Proteinosis clinical trials

The registry lists 21 studies for Pulmonary Alveolar Proteinosis across 8 countries. 6 are recruiting or about to start. 20 of them are mainly about Pulmonary Alveolar Proteinosis (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-26.

Get an email when these change. Save the Pulmonary Alveolar Proteinosis studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 9
Status unknown: 5
Recruiting: 4
Available: 1
Not yet recruiting: 1
Terminated: 1

Phase

Phase 2: 8
Phase 1: 4
Early Phase 1: 1
Phase 3: 1

Where

United States: 10
China: 4
Germany: 3
United Kingdom: 2
France: 2
Turkey: 2

Who runs them

Children's Hospital Medical Center, Cincinnati (5) · Savara Inc. (3) · Assistance Publique - Hôpitaux de Paris (2) · Shanghai Pulmonary Hospital, Shanghai, China (2) · TRPHARM (1) · Black Tie Medical, Inc. (1) · Guangzhou Institute of Respiratory Disease (1) · The Cleveland Clinic (1)

What is being tested here

Drugs under test in Pulmonary Alveolar Proteinosis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Granulocyte-Macrophage Colony-Stimulating Factor	1	0	3
Molgramostim	1	1	2
Rituximab	0	0	2
Methionine	0	0	1
Regramostim	0	0	1

Coming up

1phase 3 study under way

3studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 3, phase 3 first

Jun 2027Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP). · Phase 3 · Savara Inc.
Jun 2027Local Spraying of GM-CSF Via Bronchoscopy in the Treatment of Autoimmune Pulmonary Alveolar Proteinosis · Jiuwu Bai
Jun 2027Safety and Efficacy of PMT Therapy of hPAP · Children's Hospital Medical Center, Cincinnati

Who these studies take

Of the 4 Pulmonary Alveolar Proteinosis studies recruiting now, 3 (75%) set no upper age limit and 1 (25%) stop at 75 or younger. 3 (75%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 4
Age	Women	Men
10	3 (75%)	3 (75%)
18	4 (100%)	4 (100%)
30	3 (75%)	3 (75%)
40	3 (75%)	3 (75%)
50	3 (75%)	3 (75%)
65	3 (75%)	3 (75%)
75	3 (75%)	3 (75%)
85	3 (75%)	3 (75%)

Across all 21 studies, recruiting or not: 38% stop at 75 or younger and 19% at 65; 43% take children; 0% are for women only and 0% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

Studies

Recruiting first, then most recently updated. Showing 21 of 21. search them.